
Acquisition - November 7, 2014
MedImmune Acquires Definiens
MedImmune, AstraZeneca’s global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has developed an imaging and data analysis technology known as Tissue Phenomics™. The new technology significantly improves the identification of biomarkers in tumor tissue. According to the agreement, MedImmune will acquire 100 percent of Definiens’ […]

Acquisition - November 4, 2014
Medimmune acquires Definiens
AstraZeneca has announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumour tissue. Under the terms of the agreement, MedImmune will […]